10 Overlooked Growth Stocks to Buy Now
On April 14, Tom Lee, Fundstrat's Head of Research, joined CNBC's 'Power Lunch' to discuss his outlook on equities.
Zai Lab Ltd (ZLAB)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | RA Capital Management Peter Kolchinsky | 5,707,262 | $107,353,598 | 1.14% | |
| 2. | Citadel Investment Group Ken Griffin | 1,688,632 | $31,763,167 | +1% | 0.01% |
| 3. | BAMCO Inc. Ron Baron | 1,658,318 | $31,192,962 | +17% | 0.09% |
| 4. | ADAR1 Capital Management Daniel Schneeberger | 1,425,367 | $26,811,153 | +15% | 1.58% |
| 5. | Rock Springs Capital Management Kris Jenner, Gordon Bussard, Graham Mcphail | 814,707 | $15,324,639 | +1% | 0.9% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $18.91 | 1,731 | $32,733.21 | 56,630 | 2026-03-17 | Filing | |
| $28.91 | 10,000 | $289,100.00 | 86,604 | 2025-09-10 | Filing | |
| $21.40 | 3,000 | $64,200.00 | 31,684 | 2024-05-13 | Filing | |
| $20.83 | 3,000 | $62,490.00 | 23,527 | 2024-03-01 | Filing | |
| $29.90 | 4,000 | $119,600.00 | 20,527 | 2023-12-14 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $20.19 | 3,517 | $71,008.23 | 19,849 | 2026-05-14 | Filing | |
| $20.09 | 50,000 | $1,004,575.00 | 1,122,626 | 2026-05-14 | Filing | |
| $20.22 | 33,769 | $682,886.85 | 1,122,626 | 2026-05-13 | Filing | |
| $19.44 | 16,231 | $315,582.58 | 1,156,395 | 2026-05-13 | Filing | |
| $20.45 | 3,017 | $61,691.62 | 117,602 | 2026-04-06 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 6,574,032 | $123,657,542 | 1.23% | |
| 2. | 1,902,320 | $35,782,639 | 0.92% | |
| 3. | 1,262,391 | $23,745,575 | 0% | |
| 4. | 865,146 | $16,273,397 | 0% | |
| 5. | 504,191 | $9,483,833 | 0% |
News See All
JPMorgan Cuts PT on Zai Lab Limited (ZLAB) to $32 From $39 - Here's Why
Zai Lab Limited (NASDAQ:ZLAB) is one of the best high growth healthcare stocks to buy now. JPMorgan cut the price target on Zai Lab Limited (NASDAQ:ZLAB) to $32 from $39 on March 18, reiterating an ...
11 High Growth Healthcare Stocks to Buy Now
On March 26, Stephanie Link, Hightower chief investment strategist, appeared on CNBC's ‘Squawk Box’ to talk about the latest market trends, where investors can find opportunities, and the effects ...
Zai Lab Limited (NASDAQ:ZLAB) Q4 2025 Earnings Call Transcript
Operator: Hello, ladies and gentlemen. Thank you for standing by, and welcome to Zai Lab's Fourth Quarter and Full Year 2025 Financial Results Conference Call.
UBS Sees Zai Lab (ZLAB) as a Rising Global Biopharma Platform
Zai Lab Limited (NASDAQ:ZLAB) ranks among the best high growth Chinese stocks to buy.
8 High Growth Chinese Stocks To Buy
China's stock market boom is attracting heightened attention from regulators after trading activity reached record highs, causing officials to take steps to limit leverage, even though a number of investors...
12 Stocks that Will Bounce Back According to Wall Street Analysts
On January 5, Reuters reported that many analysts believe global investors will actively look for opportunities in undervalued areas of the financial markets in 2026.
Zai Lab (ZLAB) Remains a Buy Amid Strong Commercial and Pipeline Momentum
As of November 27, Zai Lab Limited (NASDAQ:ZLAB) is a consensus Buy with over 90% analysts covering it having a Buy, Strong Buy, or equivalent rating.
12 Oversold Global Stocks to Invest In
Appearing in an interview with CNBC on November 21, 2025, David Katz of Matrix Asset Advisors called widespread weakness a potential entry point, saying that the current correction is “much closer to...
Zai Lab Limited (NASDAQ:ZLAB) Q3 2025 Earnings Call Transcript
Operator: Hello, ladies and gentlemen. Thank you for standing by, and welcome to Zai Lab's Third Quarter 2025 Financial Results Conference Call. [Operator Instructions].